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Background : Warfarin is a widely used oral anticoagulant with broad within-and between-individual dose requirements. Warfarin concentrations can be monitored by assessing its pharmacologic effects on International Normalized Ratio (INR). However, this approach has not been applied in the routine clinical management of patients receiving warfarin therapy. We performed a plasma warfarin assay using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) to determine if such an assay can be utilized in routine clinical practice.
Methods : We included a total of 105 patients with atrial fibrillation, and who were receiving warfarin for more than 1 yr. The plasma concentrations of total warfarin and 7-hydroxywarfarin were determined by HPLC-MS/MS (Waters, UK). We assessed the association between warfarin dose, concentration, and INR as well as the effects of these factors on warfarin concentrations.
Results : The mean maintenance dose of warfarin in 105 patients was 4.1±1.3 mg/day (range, 1.7-8.0 mg/day) and their mean plasma warfarin concentration was 1.3±0.5 mg/L. We defined a concentration range of 0.6-2.6 mg/L (corresponding to the 2.5th to 97.5th percentile range of the Plasma warfarin levels in the 74 patients showing INR within target range) as the therapeutic range for warfarin. The correlation of warfarin dose with warfarin concentration (r 2 =0.259, P<0.001) was higher than that with INR (r
INTRODUCTION
Warfarin is widely used as an oral anticoagulant for the treatment of conditions associated with high risk of thromboembolic events such as atrial fibrillation, deep vein thrombosis, mechanical heart valve replacement, and pulmonary embolism [1, 2] . However, warfarin has a narrow therapeutic index and may be associated with adverse events.
Inadequate or excessive anticoagulation may result in substantial morbidity and mortality due to thromboembolic complications or bleeding [3, 4] . Life-threatening bleeding episodes after initiation of warfarin therapy have been reported in approximately 12% of patients; furthermore, elderly patients are especially vulnerable to such events, and there is also a substantial risk of developing warfarin resistance [5] [6] [7] [8] [9] . During maintenance therapy, only 50-60% of patients can be expected to achieve their target INR range [10, 11] . Therefore, much effort has to be directed toward monitoring the safety and efficacy of warfarin treatment and developing strategies to predict the patient' s response to this drug [12] .
There is a marked within-and between-individual variability in warfarin dose requirements and different factors associated with patient response to warfarin treatment, which makes the monitoring of warfarin therapy more difficult [13] [14] [15] [16] [17] [18] [19] . With regard to the ethnic differences among patients, it has been shown that Asian populations require a markedly lower warfarin maintenance dose than Caucasians and African-Americans; however, the mechanisms underlying these differences still remain elusive [20, 21] .
Currently, the required dose of warfarin is monitored based on its pharmacodynamic effects on the blood prothrombin time (PT) by using the standard international normalized ratio (INR) [22] . The assessment of plasma warfarin concentration may be valuable in some clinical situ- 
MATERIALS AND METHODS

Study subjects
The Institutional Review Board approved the study pro- 
Determination of warfarin and 7-hydroxywarfarin concentrations in plasma
The plasma concentrations of total warfarin and 7-hy- 
Statistical analysis
Continuous variables were reported as mean±SD, medians, and ranges. 
RESULTS
One hundred and five patients participated in the present study. The warfarin dose, total plasma warfarin concentration, and warfarin to 7-hydroxywarfarin ratio for the 74 patients who were well controlled are presented in Fig. 3 .
The mean warfarin maintenance dose was 4.1 mg/day.
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Min-Jung Kwon, Hee-Jin Kim, Jong-Won Kim, et al. is at least partly responsible for warfarin resistance, which causes significant differences in patient responses to warfarin therapy [29, 30] . In our study, 2 patients receiving 6 mg/day and 5 mg/day warfarin showed high plasma war- 
